Intellia Therapeutics, Inc.NTLANASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P72
Within normal range
vs 2Y Ago
1.2x
Modest growth
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.90% |
| Q3 2025 | 22.81% |
| Q2 2025 | 33.11% |
| Q1 2025 | -74.81% |
| Q4 2024 | -0.42% |
| Q3 2024 | -45.80% |
| Q2 2024 | 51.78% |
| Q1 2024 | -29.67% |
| Q4 2023 | 8.21% |
| Q3 2023 | -12.24% |
| Q2 2023 | 17.38% |
| Q1 2023 | -21.65% |
| Q4 2022 | -14.44% |
| Q3 2022 | 7.72% |
| Q2 2022 | -6.63% |
| Q1 2022 | -46.02% |
| Q4 2021 | 15.95% |
| Q3 2021 | -22.73% |
| Q2 2021 | -1.16% |
| Q1 2021 | -30.20% |
| Q4 2020 | -40.86% |
| Q3 2020 | -149.74% |
| Q2 2020 | 248.96% |
| Q1 2020 | -34.48% |
| Q4 2019 | -12.63% |
| Q3 2019 | 8.05% |
| Q2 2019 | -29.01% |
| Q1 2019 | -151.26% |
| Q4 2018 | 31.44% |
| Q3 2018 | 44.64% |
| Q2 2018 | -26.59% |
| Q1 2018 | 16.60% |
| Q4 2017 | -26.12% |
| Q3 2017 | -7.76% |
| Q2 2017 | -37.55% |
| Q1 2017 | 20.90% |
| Q4 2016 | -89.36% |
| Q3 2016 | -111.27% |
| Q2 2016 | 817.02% |
| Q1 2016 | -71.57% |